Loading
Loading
Research Overview
Calf-thymus polypeptide complex; proposed to restore T-cell maturation and differentiation capacity via thymic signalling peptides in the context of age-related thymic involution, modulating T-lymphocyte subset ratios and immune competence markers.
Thymalin is a heterogeneous polypeptide complex derived from calf thymus gland tissue, developed within the Russian bioregulator research tradition pioneered by Vladimir Khavinson and colleagues. Unlike thymosin alpha-1 (a defined single peptide) or thymulin (a nonapeptide secreted by thymic epithelial cells), thymalin is an incompletely characterised mixture of thymic peptides standardised by biological activity rather than chemical identity.
Russian and Eastern European clinical practice has applied thymalin as an immune restoration therapy in elderly patients with immune senescence (age-related immune decline), patients recovering from serious illness or surgery, and individuals with chronic immune suppression. The proposed mechanism involves thymus-derived signalling peptides restoring T-cell maturation and differentiation capacity that declines with age as thymic involution progresses.
Clinical data from Soviet and Russian studies is largely unavailable in the Western scientific literature due to language and access barriers. The evidence base accessible to Western researchers is limited, and thymalin sits at the intersection of bioregulator research and geroprotective medicine. Its evidence classification is anecdotal by conventional standards.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, thymalin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Thymalin research is most relevant to protocols examining:
Thymic polypeptide and immune restoration research
Age-related thymic involution and T-cell competence studies
T-lymphocyte subset modulation investigations
Longevity protocols targeting immune senescence via thymic peptides
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: Minutes (plasma); biological effects persist days). Review data, confirm baseline recovery before any repeat protocol.
Calf-thymus polypeptide complex; proposed to restore T-cell maturation and differentiation capacity via thymic signalling peptides in the context of age-related thymic involution, modulating T-lymphocyte subset ratios and immune competence markers.
| Parameter | Value |
|---|---|
| Dose range | 5–10 mg/day for 10-day pulse cycle |
| Schedule | 10-day pulse, then off |
| Route | Intramuscular, Subcutaneous |
| Half-life | Minutes (plasma); biological effects persist days |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.